Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Knowing when to assess your retirement strategy ensures your financial plan remains effective. Regular evaluations can lead to better outcomes.
21,973 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
A durable capex cycle is forming around upgrading the power grid to handle AI, EV charging, and reshoring needs. Anal...
Cardano has integrated Scorechain’s analytics platform to deliver institutional-grade compliance tools for ADA. The m...
At Consensus 2026 in Miami, Pi Network’s Dr. Chengdiao Fan laid out a vision for utility-driven tokens and real-world...
Disney beats Q2 expectations, sending Wall Street into a target-upgrade cycle. JPMorgan, Barclays and Guggenheim lift...
A rapid Trump-backed rally has pushed stocks to fresh highs, yet selective bargains remain. The market shows pockets ...
Rising college costs and changing job markets are pushing families to rethink Ivy League prestige. A new wave of non-...
Aramco’s chief executive warned that the oil market won’t return normal this year if the Iran conflict isn’t resolved...
XRP jumps above $1.45 on strong Upbit demand in South Korea, with institutional buying and tokenized treasuries suppo...
AMD’s latest earnings reinforce its role in the AI infrastructure wave, setting up this stock biggest bet for May as ...
As AI data centers expand, three optics names have led the charge in 2026. Through May, AAOI has surged, while LITE a...
India tightened gold import rules this week, a move officials say protects the rupee, but traders warn it could bolst...